A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban

BACKGROUND: Currently, there are no direct comparisons of apixaban and rivaroxaban, two new oral direct factor Xa inhibitors approved for management of thromboembolic disorders. OBJECTIVE: Compare the pharmacokinetics and anti-factor Xa activity (AXA) of apixaban and rivaroxaban. METHODS: In this ra...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Pharmacol
Hlavní autoři: Frost, Charles, Song, Yan, Barrett, Yu Chen, Wang, Jessie, Pursley, Janice, Boyd, Rebecca A, LaCreta, Frank
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2014
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4235474/
https://ncbi.nlm.nih.gov/pubmed/25419161
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CPAA.S61131
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky